Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Neoplasm Metastasis 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stage I Prostate Adenocarcinoma 1 Sarcoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibrosarcoma 1 Melanoma 1 Hemangiosarcoma 1 Gastrointestinal Stromal Tumors 1 Colorectal Neoplasms 1

Interventions

Doxorubicin 57 Radiotherapy 40 Ifosfamide 39 Gemcitabine 38 Cyclophosphamide 29 Docetaxel 25 pazopanib 24 pembrolizumab 22 Filgrastim 22 Nivolumab 20 Trabectedin 19 Etoposide 18 Cisplatin 17 Surgical Procedures, Operative 16 Blood Specimen Collection 15 Radiation 12 Carboplatin 12 liposomal doxorubicin 11 Ipilimumab 11 apatinib 10 anlotinib 10 Vincristine 10 Radiosurgery 10 Peripheral Blood Stem Cell Transplantation 10 Melphalan 10 Magnetic Resonance Spectroscopy 10 Drug Therapy 10 Bevacizumab 10 Temozolomide 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡